Biologics Market Size, Scope, Revenue Report 2026 to 2035
Segmentation of Biologics Market-
Biologics Market By Source
- Microbial
- Mammalian
- Others
Biologics Market By Product
- MABs
- Vaccines
- Hormones
- Therapeutic Enzymes
- Recombinant Proteins
- Antisense, RNAi & Molecular Therapy
- Blood Factors and Anticoagulants
- Allergenic extracts
- Human Cells and Tissues
- Proteins
- Gene Therapies
- Cellular Therapies
- Others
Biologics Market By Disease
- Oncology
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
Biologics Market By Manufacturing
- Outsourced
- In-house
Biologics Market By Route of Administration
- Oral
- Others (IV and IP)
Biologics Market By Drug Classification
- Branded Drugs
- Generic Drugs
Biologics Market By Mode of Purchase
- Prescription Drugs
- Over The Counter (OTC) Drugs
Biologics Market By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Biologics Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biologics Market Snapshot
Chapter 4. Global Biologics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Route of Administration Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Source Estimates & Trend Analysis
5.1. by Source & Market Share, 2025 & 2035
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Source:
5.2.1. Microbial
5.2.2. Mammalian
5.2.3. Others
Chapter 6. Market Segmentation 2: by Product Estimates & Trend Analysis
6.1. by Product & Market Share, 2025 & 2035
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Product:
6.2.1. MABs
6.2.2. Vaccines
6.2.3. Hormones
6.2.4. Therapeutic Enzymes
6.2.5. Recombinant Proteins
6.2.6. Antisense, RNAi & Molecular Therapy
6.2.7. Blood Factors and Anticoagulants
6.2.8. Allergenic extracts
6.2.9. Human Cells and Tissues
6.2.10. Proteins
6.2.11. Gene Therapies
6.2.12. Cellular Therapies
6.2.13. Others
Chapter 7. Market Segmentation 3: by Disease Estimates & Trend Analysis
7.1. by Disease & Market Share, 2025 & 2035
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Disease:
7.2.1. Oncology
7.2.2. Immunological Disorders
7.2.3. Cardiovascular Disorders
7.2.4. Hematological Disorders
7.2.5. Others
Chapter 8. Market Segmentation 4: by Manufacturing Estimates & Trend Analysis
8.1. by Manufacturing & Market Share, 2025 & 2035
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Manufacturing:
8.2.1. Outsourced
8.2.2. In-house
Chapter 9. Market Segmentation 5: by Distribution Channel Estimates & Trend Analysis
9.1. by Distribution Channel & Market Share, 2025 & 2035
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Distribution Channel:
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
Chapter 10. Market Segmentation 6: by Route of Administration Estimates & Trend Analysis
10.1. by Route of Administration& Market Share, 2025 & 2035
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Route of Administration:
10.2.1. Oral
10.2.2. Others (IV and IP)
Chapter 11. Market Segmentation 7: by Drug Classification Estimates & Trend Analysis
11.1. by Drug Classification & Market Share, 2025 & 2035
11.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Drug Classification:
11.2.1. Branded Drugs
11.2.2. Generic Drugs
Chapter 12. Market Segmentation 8: by Mode of Purchase Estimates & Trend Analysis
12.1. by Mode of Purchase & Market Share, 2025 & 2035
12.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Mode of Purchase:
12.2.1. Prescription Drugs
12.2.2. Over The Counter (OTC) Drugs
Chapter 13. Biologics Market Segmentation 9: Regional Estimates & Trend Analysis
13.1. North America
13.1.1. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2022 - 2035
13.1.2. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022 - 2035
13.1.3. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2022 - 2035
13.1.4. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2022 - 2035
13.1.5. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022 - 2035
13.1.6. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022 - 2035
13.1.7. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2022 - 2035
13.1.8. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2022 - 2035
13.1.9. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2022 - 2035
13.2. Europe
13.2.1. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2022 - 2035
13.2.2. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022 - 2035
13.2.3. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2022 - 2035
13.2.4. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2022 - 2035
13.2.5. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022 - 2035
13.2.6. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022 - 2035
13.2.7. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2022 - 2035
13.2.8. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2022 - 2035
13.2.9. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2022 - 2035
13.3. Asia Pacific
13.3.1. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2022 - 2035
13.3.2. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022 - 2035
13.3.3. Asia-Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2022 - 2035
13.3.4. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2022 - 2035
13.3.5. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022 - 2035
13.3.6. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022 - 2035
13.3.7. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2022 - 2035
13.3.8. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2022 - 2035
13.3.9. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2022 - 2035
13.4. Latin America
13.4.1. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2022 - 2035
13.4.2. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022 - 2035
13.4.3. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2022 - 2035
13.4.4. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2022 - 2035
13.4.5. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022 - 2035
13.4.6. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022 - 2035
13.4.7. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2022 - 2035
13.4.8. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2022 - 2035
13.4.9. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2022 - 2035
13.5. Middle East & Africa
13.5.1. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2022 - 2035
13.5.2. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022 - 2035
13.5.3. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2022 - 2035
13.5.4. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2022 - 2035
13.5.5. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022 - 2035
13.5.6. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022 - 2035
13.5.7. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2022 - 2035
13.5.8. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2022 - 2035
13.5.9. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2022 - 2035
Chapter 14. Competitive Landscape
14.1. Major Mergers and Acquisitions/Strategic Alliances
14.2. Company Profiles
14.2.1. Abbvie Inc.
14.2.2. Amgen
14.2.3. AstraZeneca
14.2.4. Bayer AG
14.2.5. Celltrion Inc.
14.2.6. Addgene
14.2.7. Eli Lilly & Company
14.2.8. F. Hoffmann-La Roche Ltd
14.2.9. GSK group of companies
14.2.10. Johnson & Johnson Services, Inc
14.2.11. Merck & Co. Inc
14.2.12. Novartis AG
14.2.13. Novo Nordisk A/S
14.2.14. Pfizer Inc.
14.2.15. Precision Biologics, Inc.
14.2.16. Samsung Biologics
14.2.17. Sanofi
14.2.18. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Biologics Market Size is valued at USD 456.24 Bn in 2025 and is predicted to reach USD 973.58 Bn by the year 2035.
Biologics Market expected to grow at a 8.0% CAGR during the forecast period for 2026-2035.
Samsung BioLogics; Amgen; Novo Nordisk A/S; AbbVie Inc.; Sanofi; Pfizer Inc.; Inc.; GSK group of companies; Merck & Co., Celltrion; Precision Biologic
Biologics market is segmented based on source, product, disease, manufacturing, route of administration, drug classification, mode of purchase, distribution channel.
North America region is leading the Biologics Market.